These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 11920637

  • 1. alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin.
    Taga T, Suzuki A, Gonzalez-Gomez I, Gilles FH, Stins M, Shimada H, Barsky L, Weinberg KI, Laug WE.
    Int J Cancer; 2002 Apr 10; 98(5):690-7. PubMed ID: 11920637
    [Abstract] [Full Text] [Related]

  • 2. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist.
    MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA, Laug WE.
    Neurosurgery; 2001 Jan 10; 48(1):151-7. PubMed ID: 11152340
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The human integrin alpha 8 beta 1 functions as a receptor for tenascin, fibronectin, and vitronectin.
    Schnapp LM, Hatch N, Ramos DM, Klimanskaya IV, Sheppard D, Pytela R.
    J Biol Chem; 1995 Sep 29; 270(39):23196-202. PubMed ID: 7559467
    [Abstract] [Full Text] [Related]

  • 5. A selective cyclic integrin antagonist blocks the integrin receptors alphavbeta3 and alphavbeta5 and inhibits retinal pigment epithelium cell attachment, migration and invasion.
    Hoffmann S, He S, Jin M, Ehren M, Wiedemann P, Ryan SJ, Hinton DR.
    BMC Ophthalmol; 2005 Jun 29; 5():16. PubMed ID: 15987521
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins.
    Mitjans F, Meyer T, Fittschen C, Goodman S, Jonczyk A, Marshall JF, Reyes G, Piulats J.
    Int J Cancer; 2000 Sep 01; 87(5):716-23. PubMed ID: 10925366
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
    Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL.
    Cancer Res; 2002 Aug 01; 62(15):4263-72. PubMed ID: 12154028
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.
    Li L, Wartchow CA, Danthi SN, Shen Z, Dechene N, Pease J, Choi HS, Doede T, Chu P, Ning S, Lee DY, Bednarski MD, Knox SJ.
    Int J Radiat Oncol Biol Phys; 2004 Mar 15; 58(4):1215-27. PubMed ID: 15001266
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.